Biopharmaceutical company Raptor Pharmaceutical Corp (NasdaqGM:RPTP) reported on Thursday the receipt of marketing approval from the European Commission (EC) for PROCYSBI for the treatment of proven nephropathic cystinosis EC in the European Union (EU).

There are three types of cystinosis, which can appear at any age: infantile nephropathic (usually from 6-8 months after birth), late-onset nephropathic (usually between ages 12 and 13), and benign non-nephropathic (usually in adulthood).

The acquisition sees the addition of Procysbi, a treatment for nephropathic cystinosis, a rare metabolic disorder, and Quinsair, which is given to cystic fibrosis patients, to Horizons rare disease portfolio.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.